|
|
Volumn 7, Issue 2, 2008, Pages 151-153
|
|
Human versus HIV: Round 2 defeat in AIDS vaccine development
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADENOVIRUS VECTOR;
HUMAN IMMUNODEFICIENCY VIRUS VACCINE;
MRKAD5 VACCINE;
POLIOMYELITIS VACCINE;
RESPIRATORY SYNCYTIAL VIRUS VACCINE;
UNCLASSIFIED DRUG;
ACQUIRED IMMUNE DEFICIENCY SYNDROME;
ADENOVIRUS 5;
CELLULAR IMMUNITY;
CLINICAL TRIAL;
DRUG EFFICACY;
DRUG FORMULATION;
DRUG INDUSTRY;
DRUG MONITORING;
DRUG RESEARCH;
DRUG SAFETY;
EDITORIAL;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS;
HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT;
IMMUNIZATION;
IMMUNOGENICITY;
IMMUNOLOGY;
MEDICAL SOCIETY;
NATIONAL INSTITUTE OF ALLERGY AND INFECTOUS DISEASE;
NONHUMAN;
POLIOMYELITIS;
PRIORITY JOURNAL;
RESPIRATORY TRACT INFECTION;
VACCINATION;
ADENOVIRIDAE;
AIDS VACCINES;
CLINICAL TRIALS, PHASE II AS TOPIC;
GENETIC VECTORS;
HIV ANTIGENS;
HIV INFECTIONS;
HIV-1;
HUMANS;
IMMUNITY, CELLULAR;
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (U.S.);
PRIVATE SECTOR;
TREATMENT FAILURE;
UNITED STATES;
|
|
EID: 40549094977
PISSN: 14760584
EISSN: 17448395
Source Type: Journal
DOI: 10.1586/14760584.7.2.151 Document Type: Editorial |
|
Times cited : (12)
|
|
References (16)
|
